20393-5 |
Sample hemolyzed |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Sample hemolyzed [Presence] of Serum or Plasma Qualitative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
20393-5 |
|
|
|
|
Observation |
|
|
|
0 |
Sample Hemolyzed SerPl Ql |
|
|
|
|
|
Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SPEC; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
20394-3 |
Sample lipemic |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Sample lipemic [Presence] of Serum or Plasma Qualitative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
20394-3 |
|
|
|
|
Observation |
|
|
|
0 |
Sample Lipemic SerPl Ql |
|
|
|
|
|
Milky; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SPEC; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
20395-0 |
Sample integrity |
Type |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Sample integrity [Type] of Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
Icteric;Hemolyzed;Lipemic |
|
|
|
|
|
SPEC |
|
20395-0 |
|
|
|
|
Observation |
|
|
|
0 |
Sample Integrity SerPl |
|
|
|
|
|
Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SPEC; SR; Typ |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
20396-8 |
levoFLOXacin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
levoFLOXacin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
20396-8 |
|
MIC |
|
|
Observation |
|
|
|
0 |
levoFLOXacin Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
20397-6 |
Sparfloxacin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Sparfloxacin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
20397-6 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Sparfloxacin Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zagam |
2.19 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
20398-4 |
Nuclear Ab pattern.homogeneous |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Homogenous nuclear Ab pattern [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
20398-4 |
|
|
|
|
Both |
|
|
|
0 |
ANA Homogen Titr Ser |
|
|
|
Y |
|
ANA; ANA Homogen; ANA Pat; ANF; Antinuclear antibody; Dilution factor; Dilution Factor (Titer); Homogen; NA; Nuc; Point in time; Random; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
20399-2 |
Nuclear Ab pattern.nucleolar |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Nucleolar nuclear Ab pattern [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
20399-2 |
|
|
|
|
Both |
|
|
|
0 |
ANA nucleolar Titr Ser |
|
|
|
Y |
|
ANA; ANA nucleolar; ANA Pat; ANF; Antinuclear antibody; Dilution factor; Dilution Factor (Titer); NA; Nuc; Point in time; Random; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
204-8 |
Colistin |
Susc |
Isolate |
Pt |
Qn |
MLC |
|
ACTIVE |
Colistin [Susceptibility] by Minimum lethal concentration (MLC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
204-8 |
|
MLC |
|
|
Observation |
|
|
|
0 |
Colistin Islt MLC |
|
|
|
Y |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Colmycin; Colymycin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MBC; Minimum bactericidal concentration; Minimum lethal concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
2040-4 |
Cardiolipin |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Cardiolipin [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
2040-4 |
|
|
|
|
Both |
|
|
|
0 |
Cardiolipin Ser-mCnc |
|
|
|
Y |
|
Cardio; Cardiolip; Cardiolipn; Cardiolpn; CL; COAGULATION; Hematology; Heme; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.34 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
20400-8 |
Nuclear Ab pattern.smooth nuclear envelope |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Smooth nuclear envelope nuclear Ab pattern [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
20400-8 |
|
|
|
|
Both |
|
|
|
0 |
ANA smooth nucl env Titr Ser |
|
|
|
Y |
|
ANA; ANA Pat; ANA smooth nucl env; ANF; Antinuclear antibody; Dilution factor; Dilution Factor (Titer); Membranous; NA; Nuc; Nuclear membrane; Nuclear rim; Point in time; Random; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
Release 2.70: COMPONENT: Updated "rim" in Component to "smooth nuclear envelope" to align with current nomenclature (https://www.anapatterns.org/view_pattern.php?pattern=11); |
0 |
20401-6 |
Nuclear Ab pattern.speckled |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Speckled nuclear Ab pattern [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
20401-6 |
|
|
|
|
Both |
|
|
|
0 |
ANA Speckled Titr Ser |
|
|
|
Y |
|
ANA; ANA Pat; ANA Speckled; ANF; Antinuclear antibody; Dilution factor; Dilution Factor (Titer); NA; Nuc; Point in time; Random; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
20402-4 |
Cells.CD16+CD56+ |
NCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD16+CD56+ cells [#/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
/uL |
|
|
|
|
|
|
CELLMARK |
|
20402-4 |
|
|
|
|
Both |
|
|
|
0 |
CD16+CD56+ Cells # Bld |
|
|
|
Y |
|
#; ABS; absolute; absolutes; Blood; CD16 Cells; CD16+CD56+ Cells; Cell; CELL MARKERS; Cellularity; Cnt; Count; Count/volume; CT; FCGR3A; Leu11; Leu-11; Leu11b; Leu-11B; Leu19; Leu-19; NCAM; Neural cell adhesion molecule; NKH1; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
1.0m |
|
|
|
|
|
|
|
/uL |
|
|
|
0 |
20403-2 |
Fibronectin.fetal |
MCnc |
Vag |
Pt |
Qn |
|
|
ACTIVE |
Fibronectin.fetal [Mass/volume] in Vaginal fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHEM |
|
20403-2 |
|
|
|
|
Both |
|
|
|
0 |
Fibronectin Fetal Vag-mCnc |
|
|
|
Y |
|
Chemistry; fFN; Fibronectin Fetal; Fn; Genital vaginal; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
20404-0 |
Fibronectin.fetal |
PrThr |
Vag |
Pt |
Ord |
|
|
ACTIVE |
Fibronectin.fetal [Presence] in Vaginal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
20404-0 |
|
|
|
|
Both |
|
|
|
0 |
Fibronectin Fetal Vag Ql |
|
|
|
|
|
Chemistry; fFN; Fibronectin Fetal; Fn; Genital vaginal; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UniversalLabOrders; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
20405-7 |
Urobilinogen |
MCnc |
Urine |
Pt |
SemiQn |
Test strip |
|
ACTIVE |
Urobilinogen [Mass/volume] in Urine by Test strip |
|
MAJ |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
UA |
|
20405-7 |
|
Test strip |
|
|
Both |
|
|
|
0 |
Urobilinogen Ur Strip-mCnc |
|
|
|
Y |
|
Dip stick; Dipstick; Level; Mass concentration; Point in time; Random; SmQn; UA; UBG; UniversalLabOrders; UR; URINALYSIS; Urn; Urobili; Urobilngn |
2.75 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
20406-5 |
Glucose |
MFr |
Urine |
Pt |
Qn |
Test strip |
|
DEPRECATED |
Deprecated Glucose [Mass/volume] in Urine by Test strip |
|
MIN |
DefinitionDescription |
|
|
% |
.10%;.25%;.5%;1%;2% |
|
|
|
|
|
UA |
|
20406-5 |
|
Test strip |
|
|
Both |
|
|
|
0 |
Deprecated Glucose Fr Ur Strip |
|
|
|
Y |
|
Dip stick; Dipstick; Glu; Gluc; Glucoseur; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; URINALYSIS; Urn |
2.7 |
1.0m |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
20407-3 |
Nitrite |
MCnc |
Urine |
Pt |
SemiQn |
Test strip |
|
ACTIVE |
Nitrite [Mass/volume] in Urine by Test strip |
|
MAJ |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
UA |
|
20407-3 |
|
Test strip |
|
|
Observation |
|
|
|
0 |
Nitrite Ur Strip-mCnc |
|
|
|
Y |
|
Dip stick; Dipstick; Level; Mass concentration; NO2; Point in time; Random; SmQn; UA; UR; URINALYSIS; Urn |
2.75 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
20408-1 |
Leukocytes |
NCnc |
Urine |
Pt |
SemiQn |
Test strip |
|
ACTIVE |
Leukocytes [#/volume] in Urine by Test strip |
|
MAJ |
DefinitionDescription |
|
|
Leu/uL; WBCS/uL |
Neg;25;50;100;500 |
|
|
|
|
|
UA |
|
20408-1 |
|
Test strip |
|
|
Observation |
|
|
|
0 |
WBC # Ur Strip |
|
|
|
Y |
|
#; ABS; absolute; absolutes; Cnt; Count; Count/volume; CT; Dip stick; Dipstick; Leuc; Leuk; Leukocyte; Lkcs; Number concentration; Number Concentration (count/vol); Point in time; Random; SmQn; UA; UR; URINALYSIS; Urn; WBC; WBCs; White blood cell; White blood cells |
2.75 |
1.0m |
|
|
|
|
|
|
|
/uL |
|
|
|
0 |
20409-9 |
Erythrocytes |
NCnc |
Urine |
Pt |
SemiQn |
Test strip |
|
ACTIVE |
Erythrocytes [#/volume] in Urine by Test strip |
|
MAJ |
DefinitionDescription |
|
|
ERY/uL; RBCS/uL |
|
|
|
|
|
|
UA |
|
20409-9 |
|
Test strip |
|
|
Observation |
|
|
|
0 |
RBC # Ur Strip |
|
|
|
Y |
|
#; ABS; absolute; absolutes; Cnt; Count; Count/volume; CT; Dip stick; Dipstick; Discocytes; Erthrocyte; Erythrocyte; Number concentration; Number Concentration (count/vol); Point in time; Random; RBC; RBCS; Red blood cell; Red blood cells; Red blood corpuscle; Red blood corpusles; Red cell; Red cells; SmQn; UA; UR; URINALYSIS; Urn |
2.75 |
1.0m |
|
|
|
|
|
|
|
/uL |
|
|
|
0 |
2041-2 |
Carnitine acyltransferase |
CCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Carnitine acyltransferase [Enzymatic activity/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
2041-2 |
|
|
|
|
Both |
|
|
|
0 |
Carnitine AcT SerPl-cCnc |
|
|
|
Y |
|
Carnitine AcT; Carnitine acyl transferase; Carnitine palmitoyl transerase; Carnitine palmitoyltranserase; Carnitine.total; Catalytic Concentration; Chemistry; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
1 |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
20410-7 |
Amphetamines |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Amphetamines [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
20410-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Amphetamines Ur Cfm-mCnc |
|
|
|
Y |
|
Addiction; Amph; Amphetam; Amphetamine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Speed; UA; UR; Urn |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
20411-5 |
Barbiturates |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Barbiturates [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
20411-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Barbiturates Ur Cfm-mCnc |
|
|
|
Y |
|
Addiction; Barb; Barbiturate; Barbs; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
20412-3 |
Benzodiazepines |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Benzodiazepines [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
20412-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Benzodiaz Ur Cfm-mCnc |
|
|
|
Y |
|
Benz; Benzodiaz; Benzodiazepine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
20413-1 |
Cannabinoids |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Cannabinoids [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
20413-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Cannabinoids Ur Cfm-mCnc |
|
|
|
Y |
|
Addiction; Cannabinoid; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Delta-9-tetrahydrocannabinol; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Marijuana; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; THC; UA; UR; Urn |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
20414-9 |
Thiazides |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Thiazides [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
20414-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Thiazides Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
1.0m |
|
|
|
|
|
|
|
ng/L |
|
|
|
0 |